Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Single-blind, Partially Randomized, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Intravenous Doses of AntiBKV in Healthy Adult Volunteers.

Next Previous
Trial Profile

A Phase 1, Single-blind, Partially Randomized, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Intravenous Doses of AntiBKV in Healthy Adult Volunteers.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 20 Jun 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Potravitug (Primary)
  • Indications Polyomavirus infections
  • Focus Adverse reactions
  • Acronyms SAFE KIDNEY I
  • Sponsors Memo Therapeutics

Most Recent Events

  • 15 Jun 2023 Status changed from active, no longer recruiting to completed.
  • 25 Jan 2023 According to Vakzine Projekt Management GmbH (VPM) media release, the company announced successful completion of a clinical client project for Memo Therapeutics AG, Switzerland. The project included a Phase I trial with AntiBKV in renal transplant patients. VPM oversaw the clinical trial and performed translational project management, whereas the Australian cooperation partner and contract research organization. Accelagen managed the trial, yielding positive results, with all endpoints met
  • 24 Jan 2023 Results published in a Memo Therapeutics media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top